CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company developing transformative gene-based medicines for serious diseases, has released its financial results for Q3 ending September 30, 2024. “We are making strong progress across our pipeline of in vivo and ex vivo CRISPR-based…
Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) have announced a $350 million synthetic royalty funding agreement, tied to the U.S. net sales of Niktimvo (axatilimab-csfr). “We are thrilled to partner with Syndax, a forward-thinking oncology company with…
BioNTech SE (Nasdaq: BNTX) has announced its financial results for the third quarter and the first nine months of 2024, alongside updates on its corporate initiatives. During this period, the company successfully launched its variant-adapted COVID-19 vaccines and advanced its…
Vir Biotechnology, Inc. (Nasdaq: VIR) has released its corporate update and financial results for the third quarter ended September 30, 2024. “This quarter marked a transformative period for Vir. We have strengthened our clinical pipeline with three promising dual-masked T-cell…
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Toichi Takino; “the Company”) today announced that it has revised its consolidated financial forecasts for the full-year period ending March 2025 disclosed at the announcement of financial results ended March 2024, made on…
Global healthcare company Viatris has been named to Forbes’ World’s Top Companies for Women 2024 list, an honor awarded in collaboration with Statista, a leading statistics and industry ranking provider. “At Viatris, diverse perspectives fuel innovation and our mission to…
Astellas Pharma Inc. (TSE: 4503; President and CEO: Naoki Okamura) announced today its decision to withdraw the marketing authorization application for avacincaptad pegol intravitreal solution (ACP) from the European Medicines Agency (EMA). ACP is an investigational synthetic aptamer that inhibits…
Biogen Inc. (Nasdaq: BIIB) announced today that Michael McDonnell, Executive Vice President and Chief Financial Officer, will retire from his role on February 28, 2025. Upon his retirement, Robin Kramer, currently Biogen’s Chief Accounting Officer, will step into the Chief…
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) has announced the withdrawal of its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution (ACP). This investigational synthetic aptamer is designed to inhibit the…
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, has announced an agreement to sell 6,758,311 of its common shares at a price of $8.90 per share. This financing round is expected to close on October 29, 2024, pending…
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the closing of an oversubscribed $225 million Series B financing round. The syndicate wasled by General…
Catalent Affirms Commitment to Customers and Patients Amidst Novo Holdings Acquisition Alessandro Maselli to Remain President and CEO of Catalent Post-Acquisition Catalent, Inc. (NYSE: CTLT), a leader in the development and supply of innovative treatments for patients worldwide, has released…